Songhita Mukhopadhyay - Academia.edu (original) (raw)
Uploads
Papers by Songhita Mukhopadhyay
Pharmatimes magazine, 2019
New drug development has become a hub for pharma giants to explore various ways in which New Chem... more New drug development has become a hub for pharma giants to explore various ways in which New Chemical Entities (NCE) can be developed which turns out to be most effective and safe for the public. In this context, Patient-centricity serves the most crucial part. The basic concept of patient-centricity comes from the clinical trials being done over the patients, asking the patients in each and every stage of the clinical trial about the effect and any other side effects if any, so as to improve the properties of the Investigational New Drug (IND) and make a more personalized approach of treatment. Variable responses to drug therapy due to the standard therapy protocol of ‘one-size-fits-all’has led to severe increase in adverse reaction events. This can be reduced by involving the patients during clinical trials, by communicating with them at each and every stage of the process and asking about the outcomes they look for and the possible side effects which bother them the most. Upsurge of the therapy can be achieved by focusing on the differences due to drug which may vary from person to person. To accomplish this, individual drug responses are checked in a geographically and ethnically distinct population. Pharmacogenomics, thus playing a major role in development of personalized therapy1. However, not only genetic biomarkers (pharmacogenetics), but also non-genetic biomarkers involving proteomics and metabolomics play a major role in personalization. This review discusses about this paradigm shift from patient-centricity to personalization and various developments and future prospects in personalized medicine.
New drug development has become a hub for pharma giants to explore various ways in which New Chem... more New drug development has become a hub for pharma giants to explore various ways in which New Chemical Entities (NCE) can be developed which turns out to be most effective and safe for the public. In this context, Patient- entricity serves the most crucial part. The basic concept of patient-centricity comes from the clinical trials being done over the patients, asking the patients in each and every stage of the clinical trial about the effect and any other side effects if any, so as to improve the properties of the Investigational New Drug (IND) and make a more personalized approach of treatment .Variable responses to drug therapy due to the standard therapy protocol of ‘one-size-fits-all’ has led to severe increase in adverse reaction events. This can be reduced by involving the patients during clinical trials, by communicating with them at each and every stage of the process and asking about the outcomes they look for and the possible side effects which bother them the most. Upsurg...
World Journal of Microbiology and Biotechnology
Antimicrobial resistance (AMR) is one of the significant clinical challenges and also an emerging... more Antimicrobial resistance (AMR) is one of the significant clinical challenges and also an emerging area of concern arising from nosocomial infections of ESKAPE pathogens, which has been on the rise in both the developed and developing countries alike. These pathogens/superbugs can undergo rapid mutagenesis, which helps them to generate resistance against antimicrobials in addition to the patient’s non-adherence to the antibiotic regimen. Sticking to the idea of a ‘one-size-fits-all’ approach has led to the inappropriate administration of antibiotics resulting in augmentation of antimicrobial resistance. Antimicrobial peptides (AMPs) are the natural host defense peptides that have gained attention in the field of AMR, and recently, synthetic AMPs are well studied to overcome the drawbacks of natural counterparts. This review deals with the novel techniques utilizing the bacteriolytic activity of natural AMPs. The effective localization of these peptides onto the negatively charged bac...
Pharmatimes magazine, 2019
New drug development has become a hub for pharma giants to explore various ways in which New Chem... more New drug development has become a hub for pharma giants to explore various ways in which New Chemical Entities (NCE) can be developed which turns out to be most effective and safe for the public. In this context, Patient-centricity serves the most crucial part. The basic concept of patient-centricity comes from the clinical trials being done over the patients, asking the patients in each and every stage of the clinical trial about the effect and any other side effects if any, so as to improve the properties of the Investigational New Drug (IND) and make a more personalized approach of treatment. Variable responses to drug therapy due to the standard therapy protocol of ‘one-size-fits-all’has led to severe increase in adverse reaction events. This can be reduced by involving the patients during clinical trials, by communicating with them at each and every stage of the process and asking about the outcomes they look for and the possible side effects which bother them the most. Upsurge of the therapy can be achieved by focusing on the differences due to drug which may vary from person to person. To accomplish this, individual drug responses are checked in a geographically and ethnically distinct population. Pharmacogenomics, thus playing a major role in development of personalized therapy1. However, not only genetic biomarkers (pharmacogenetics), but also non-genetic biomarkers involving proteomics and metabolomics play a major role in personalization. This review discusses about this paradigm shift from patient-centricity to personalization and various developments and future prospects in personalized medicine.
New drug development has become a hub for pharma giants to explore various ways in which New Chem... more New drug development has become a hub for pharma giants to explore various ways in which New Chemical Entities (NCE) can be developed which turns out to be most effective and safe for the public. In this context, Patient- entricity serves the most crucial part. The basic concept of patient-centricity comes from the clinical trials being done over the patients, asking the patients in each and every stage of the clinical trial about the effect and any other side effects if any, so as to improve the properties of the Investigational New Drug (IND) and make a more personalized approach of treatment .Variable responses to drug therapy due to the standard therapy protocol of ‘one-size-fits-all’ has led to severe increase in adverse reaction events. This can be reduced by involving the patients during clinical trials, by communicating with them at each and every stage of the process and asking about the outcomes they look for and the possible side effects which bother them the most. Upsurg...
World Journal of Microbiology and Biotechnology
Antimicrobial resistance (AMR) is one of the significant clinical challenges and also an emerging... more Antimicrobial resistance (AMR) is one of the significant clinical challenges and also an emerging area of concern arising from nosocomial infections of ESKAPE pathogens, which has been on the rise in both the developed and developing countries alike. These pathogens/superbugs can undergo rapid mutagenesis, which helps them to generate resistance against antimicrobials in addition to the patient’s non-adherence to the antibiotic regimen. Sticking to the idea of a ‘one-size-fits-all’ approach has led to the inappropriate administration of antibiotics resulting in augmentation of antimicrobial resistance. Antimicrobial peptides (AMPs) are the natural host defense peptides that have gained attention in the field of AMR, and recently, synthetic AMPs are well studied to overcome the drawbacks of natural counterparts. This review deals with the novel techniques utilizing the bacteriolytic activity of natural AMPs. The effective localization of these peptides onto the negatively charged bac...